Locoregional treatment of primary tumor in synchronous metastatic head and neck squamous cell carcinomas

被引:0
|
作者
Tang, Eliane [1 ]
Schwartz, Boris [2 ]
Limkin, Elaine [1 ]
Even, Caroline [3 ]
Blanchard, Pierre [1 ]
Haddy, Nadia [2 ]
Gorphe, Philippe [4 ]
Ferrand, Francois-Regis [3 ]
Tao, Yungan [1 ]
Nguyen, Thanh-Van-France [1 ]
机构
[1] Gustave Roussy, Dept Radiat Oncol, Villejuif, France
[2] Gustave Roussy, Dept Radiat Epidemiol, Unite 1018, INSERM, Villejuif, France
[3] Gustave Roussy, Dept Head & Neck Oncol, Villejuif, France
[4] Gustave Roussy, Dept Head & Neck Surg, Villejuif, France
关键词
Head and neck; squamous cell carcinoma; metastases; locoregional treatment; radiation therapy; OPEN-LABEL; CHEMOTHERAPY; SURVIVAL; CETUXIMAB; IMPACT; MULTICENTER; RECURRENT; PLATINUM; THERAPY; CANCER;
D O I
10.1080/0284186X.2023.2209266
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PurposePatients with synchronous metastatic head and neck squamous cell carcinomas (mHNSCC) are at risk of locoregional progression associated with significant morbidity and mortality. The aim of this study is to assess whether the addition of aggressive locoregional treatment to systemic therapy could be associated with an improved overall survival (OS) compared to systemic therapy alone in upfront mHNSCC patients.Material and methodsThis retrospective study included patients presenting with previously untreated mHNSCC who underwent first-line systemic therapy at a single institution between 1998 and 2018. Locoregional treatment was defined as either exclusive locoregional radiotherapy (RT) or surgery with or without adjuvant RT.ResultsOne hundred forty-eight patients were included. Eighty patients were treated with systemic therapy alone and 68 patients were treated with a combination of locoregional treatment and systemic therapy. Median overall survival (OS) was 13 months [10.7-15] and median progression free survival (PFS) was 7.7 month [6.5-8.9]. The addition of a locoregional treatment to systemic therapy compared to systemic therapy alone was associated with improved survival (1-year OS, 65.8% vs. 41.1%, p < .001, and 1-year PFS, 42.5% vs. 18.5%, p < .001). Moreover, RT dose equal to 70 Gy was associated with even longer OS compared to a RT dose below 70 Gy and to no locoregional treatment (23.4 vs. 12.7 vs 7.5 months respectively). In a subgroup analysis on 75 patients presenting with a responding or stable metastatic disease after first-line systemic therapy, oropharyngeal primary tumor site and the addition of a locoregional treatment, especially a high radiation dose of 70 Gy, were evidenced as independent prognostic factors for improved OS.ConclusionThe addition of a high-dose RT locoregional treatment to systemic therapy is associated with prolonged OS in patients with synchronous mHNSCC and should be discussed for patients who respond to or have a stable disease after first-line systemic therapy.
引用
收藏
页码:465 / 472
页数:8
相关论文
共 50 条
  • [41] Future directions and treatment strategies for head and neck squamous cell carcinomas
    Wise-Draper, Trisha M.
    Draper, David J.
    Gutkind, J. Silvio
    Molinolo, Alfredo A.
    Wikenheiser-Brokamp, Kathryn A.
    Wells, Susanne I.
    TRANSLATIONAL RESEARCH, 2012, 160 (03) : 167 - 177
  • [42] Liquid biopsy for mutational profiling of locoregional recurrent and/or metastatic head and neck squamous cell carcinoma
    Galot, Rachel
    van Marcke, Cedric
    Helaers, Raphael
    Mendola, Antonella
    Goebbels, Rose-Marie
    Caignet, Xavier
    Ambroise, Jerome
    Wittouck, Kyril
    Vikkula, Miikka
    Limaye, Nisha
    Machiels, Jean-Pascal H.
    ORAL ONCOLOGY, 2020, 104
  • [43] Liquid biopsy for mutational profiling of locoregional recurrent and/or metastatic squamous cell carcinoma of the head and neck
    Galot, R.
    de Lummen, C. Van Marcke
    Helaers, R.
    Mendola, A.
    Goebbels, R-M.
    Caignet, X.
    Ambroise, J.
    Wittouck, K.
    Vikkula, M.
    Limaye, N.
    Machiels, J-P.
    ANNALS OF ONCOLOGY, 2019, 30
  • [44] Treatment outcomes of cetuximab-containing regimen in locoregional recurrent and distant metastatic head and neck squamous cell carcinoma
    Chen, Tien-Hua
    Pan, Yi-Ying
    Lee, Tsung-Lun
    Wang, Ling-Wei
    Tai, Shyh-Kuan
    Chu, Pen-Yuan
    Lo, Wen-Liang
    Wu, Cheng-Hsien
    Yang, Muh-Hwa
    Chang, Peter Mu-Hsin
    BMC CANCER, 2022, 22 (01)
  • [45] Treatment outcomes of cetuximab-containing regimen in locoregional recurrent and distant metastatic head and neck squamous cell carcinoma
    Tien-Hua Chen
    Yi-Ying Pan
    Tsung-Lun Lee
    Ling-Wei Wang
    Shyh-Kuan Tai
    Pen-Yuan Chu
    Wen-Liang Lo
    Cheng-Hsien Wu
    Muh-Hwa Yang
    Peter Mu-Hsin Chang
    BMC Cancer, 22
  • [46] The tumor microenvironment induces EGFR downregulation in squamous cell carcinomas of the head and neck
    Zahnreich, S.
    Brieger, J.
    Multhoff, G.
    Vaupel, P.
    Schmidberger, H.
    Mayer, A.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2017, 193 : S82 - S82
  • [47] The prognostic significance of tumor deposits in patients with head and neck squamous cell carcinomas
    Yu, Shuting
    Zhu, Yingying
    Shi, Xiaohua
    Diao, Wenwen
    Zhu, Xiaoli
    Gao, Zhiqiang
    Chen, Xingming
    ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (05)
  • [48] Progression of diploid tumor cells in aneuploid head and neck squamous cell carcinomas
    Polackova, J
    Hemmer, J
    INTERNATIONAL JOURNAL OF ONCOLOGY, 1999, 15 (02) : 315 - 320
  • [49] The Molecular Landscape of Lung Metastasis in Primary Head and Neck Squamous Cell Carcinomas
    Thirumani, Logalakshmi
    Helan, Mizpha
    Vijayaraghavan, S.
    Mohamed, Umargani Jamal
    Vimal, Sugumar
    Madar, Inamul Hasan
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (04)
  • [50] Chromosomal DNA content of primary and recurrent squamous cell carcinomas of the head and neck
    Sarker, SK
    Patel, KS
    Coleman, DV
    JOURNAL OF PATHOLOGY, 1996, 179 : A21 - A21